<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05009537</url>
  </required_header>
  <id_info>
    <org_study_id>CARTOGEN - 29BRC21.0211</org_study_id>
    <nct_id>NCT05009537</nct_id>
  </id_info>
  <brief_title>Optical Genome Mapping in Hematological Malignancies</brief_title>
  <acronym>CARTOGEN</acronym>
  <official_title>Optical Genome Mapping in Hematological Malignancies</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Brest</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Brest</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Establish the diagnostic potential of optical genome mapping in patients with suspected&#xD;
      hematologic cancer&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Anticipated">September 2021</start_date>
  <completion_date type="Anticipated">September 2026</completion_date>
  <primary_completion_date type="Anticipated">September 2022</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Establish the diagnostic potential of optical genome mapping in patients with suspected hematologic cancer</measure>
    <time_frame>2021-2026</time_frame>
    <description>identification of anomalies by mapping identical to those identified by combining conventional cytogenetics and FISH.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>identification of new chromosomal abnormalities of clinical relevance.</measure>
    <time_frame>2021-2026</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>identification of new chromosomal anomalies involved in oncogenic pathways</measure>
    <time_frame>2021-2026</time_frame>
  </secondary_outcome>
  <enrollment type="Anticipated">200</enrollment>
  <condition>MDS</condition>
  <condition>ALL</condition>
  <condition>Other Hematologic Malignant Neoplasms</condition>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      fresh cells from bone marrow frozen cells frmp bone marrow&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with suspected hemopathies&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Minor/Major Patients&#xD;
&#xD;
          -  Patients with suspected hemopathies for whom we receive a sample for diagnosis in the&#xD;
             chromosomal genetics laboratory or for whom a diagnosis of hemopathy has already been&#xD;
             made.&#xD;
&#xD;
          -  No objection made or consent given&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients under judicial protection (guardianship, curatorship, ...),&#xD;
&#xD;
          -  Refusal to participate&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Marie-Bérengère, TROADEC, PhD</last_name>
    <phone>(33)230338055</phone>
    <email>Marie-berengere.troadec@chu-brest.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Nathalie DOUET-GUILBERT, MD, PhD</last_name>
    <phone>(33)230338055</phone>
    <email>nathalie.douet-guilbert@chu-brest.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>CHRU de Brest</name>
      <address>
        <city>Brest</city>
        <zip>29609</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marie-Bérengère, TROADEC</last_name>
      <email>Marie-berengere.troadec@chu-brest.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>CH Morlaix, service d'hémato clinique</name>
      <address>
        <city>Morlaix</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Christophe NICOL, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHIC, service d'hémato clinique</name>
      <address>
        <city>Quimper</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Léanig LE CLEACH, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>CH St Brieuc, service d'hémato clinique</name>
      <address>
        <city>Saint-Brieuc</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Cédric DUCLOS, MD</last_name>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>August 16, 2021</study_first_submitted>
  <study_first_submitted_qc>August 16, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">August 17, 2021</study_first_posted>
  <last_update_submitted>August 16, 2021</last_update_submitted>
  <last_update_submitted_qc>August 16, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 17, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
    <mesh_term>Hematologic Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>All collected data that underlie results in a publication</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_time_frame>Data will be available after the publication of result and ending five years maximum following the last visit of the last patient</ipd_time_frame>
    <ipd_access_criteria>Data access requests will be reviewed by the internal committee of Brest UH. requestors will be required to sign and complete a data access agreement</ipd_access_criteria>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

